For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal res…

Breast CancerTNBC - Triple-Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more

~Estimated

~$10 – $1,125

Tempus AINCT07211178

Phase 1

A Study of a Mutant-Selective Inhibitor, CGT6297, in Patients With Advanced Solid Tumors Harboring PIK3CA Mutations

This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacod…

PIK3CA MutationsAdvanced Solid Tumors, AdultEndometrial Cancer+2 more

~Estimated

~$10 – $8,750

Cogent Biosciences, Inc.NCT07383506